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Metabolic endotoxemia has been suggested to play a role in the pathophysiology of
metaflammation, insulin-resistance and ultimately type-2 diabetes mellitus (T2DM). The
role of endogenous antimicrobial peptides (AMPs), such as the cathelicidin LL-37, in
T2DM is unknown. We report here for the first time that patients with T2DM compared to
healthy volunteers have elevated plasma levels of LL-37. In a reverse-translational
approach, we have investigated the effects of the AMP, peptide 19-2.5, in a murine
model of high-fat diet (HFD)-induced insulin-resistance, steatohepatitis and T2DM. HFD-
fed mice for 12 weeks caused obesity, an impairment in glycemic regulations,
hypercholesterolemia, microalbuminuria and steatohepatitis, all of which were
attenuated by Peptide 19-2.5. The liver steatosis caused by feeding mice a HFD
resulted in the activation of nuclear factor kappa light chain enhancer of activated B
cells (NF-ĸB) (phosphorylation of inhibitor of kappa beta kinase (IKK)a/b, IkBa,
translocation of p65 to the nucleus), expression of NF-ĸB-dependent protein inducible
nitric oxide synthase (iNOS) and activation of the NOD-, LRR- and pyrin domain-
containing protein 3 (NLRP3) inflammasome, all of which were reduced by Peptide 19-
2.5. Feeding mice, a HFD also resulted in an enhanced expression of the lipid scavenger
receptor cluster of differentiation 36 (CD36) secondary to activation of extracellular signal-org July 2021 | Volume 12 | Article 7012751
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Frontiers in Immunology | www.frontiersin.regulated kinases (ERK)1/2, both of which were abolished by Peptide 19-2.5. Taken
together, these results demonstrate that the AMP, Peptide 19-2.5 reduces insulin-
resistance, steatohepatitis and proteinuria. These effects are, at least in part, due to
prevention of the expression of CD36 and may provide further evidence for a role of
metabolic endotoxemia in the pathogenesis of metaflammation and ultimately T2DM. The
observed increase in the levels of the endogenous AMP LL-37 in patients with T2DM may
serve to limit the severity of the disease.Keywords: peptide 19-2.5, high-fat diet, type-2 diabetes, antimicrobial peptide, insulin resistance,
steatohepatitis, microalbuminuriaINTRODUCTION
Obesity and type-2 diabetes mellitus (T2DM) are associated with
metabolic endotoxemia, which has shown to play a key role in the
pathophysiology of diabetes. The leak of lipopolysaccharide (LPS)
underlying metabolic endotoxemia is due to changes in the gut
microbiota (1). Under physiological conditions, the gut epithelium
is an efficient barrier, but many factors, such as dietary alterations
can lead to changes to the intestinal epithelium. The membrane
becomes ‘leaky’ allowing LPS to enter the bloodstream. This
increase in plasma LPS in response to dietary alterations is
termed metabolic endotoxemia (2). Once LPS has entered the
bloodstream it can activate Toll-like receptor-4 (TLR4), resulting
in low-grade systemic inflammation (3).
In 2007, Cani and colleagues were the first to define metabolic
endotoxemia as a 2-3-fold increase in the level of plasma LPS due to
dietary alterations, ultimately leading to low-grade inflammation
and the development of cardiometabolic diseases. Mice-fed a high-
fat diet (HFD) for four weeks to induce metabolic endotoxemia,
showed similar levels of serum LPS to that of mice infused with LPS
continuously for four weeks (4). It should be noted that the levels of
LPS demonstrated due to a HFD are 10-15 times lower than the
levels seen in humans or animals with sepsis (4). Indeed, metabolic
endotoxemia causes low grade inflammation, while the release of
large amounts of LPS in sepsis causes a profound degree of systemic
inflammation driven by a ‘cytokine storm’.
The hypothesis that endotoxemia is the driver of the key
metabolic changes associated with obesity and diabetes is still
controversial (5). TLR4 knock-out mice, fed a HFD demonstrated
less insulin resistance and presented an improved glucose tolerance
test compared to wild-type mice (6, 7). Atherosclerosis-prone
apolipoprotein E-deficient (ApoE-/-) mice deficient in either TLR4
or myeloid differentiation primary response 88 (MyD88) develop
less atherosclerosis (8). On the other hand, the determination of LPS
relies on the limulus amebocyte lysate (LAL) assay, which is used to
detect endotoxins, however, this assay has several limitations
[reviewed in (9)]. In addition, elevated levels of LPS have also
been reported in healthy volunteers. Thus, further studies are
warranted which provide evidence that interventions, which
prevent either the development of metabolic endotoxemia or its
effects reduce the pathology of metaflammation.
Antimicrobial peptides (AMPs) were identified nearly 100 years
ago and they are an important part of innate immunity (10). LL-37org 2is the only human member of the cathelicidin family of AMPs. The
role of LL-37 (also known as CRAMP) in murine models of diet-
induced obesity is controversial as both beneficial and detrimental
effects have been reported: For example, the overexpression of LL-
37 in mice prevents diet-induced increases in cluster of
differentiation 36 (CD36) expression, hepatic steatosis and obesity
(11). In contrast, when mice in which the gene for CRAMP (LL-37)
has been deleted (Cramp-/- mice), are fed a HFD, they gain less
weight and show a higher insulin sensitivity then WT mice
challenged with the same diet. In addition, Cramp-/- mice have
lower counts of myeloid cells, monocytes and neutrophils in their
adipose tissue (12). The role of LL-37 in humans with diabetes and/
or obesity is not known.
LL-37 cannot be utilized as a therapeutic intervention, as high
doses of this peptide have substantial neuro-and nephrotoxicity
(13). Thus, synthetic AMPs, such as peptide 19-2.5, were
developed with reduced toxicity as a potential lead candidate
for the treatment of diseases in which AMPs may be useful
including T2DM. Peptide 19-2.5 was designed to have a maximal
binding capacity for the lipid-A moiety of LPS and to neutralize
LPS and has shown to attenuate effectively both systemic
inflammation and organ injury/dysfunction which is associated
with sepsis. This is achieved by the peptide being able to bind to
and inactive LPS (14, 15).
Here, we have investigated the levels of LL-37 in healthy
volunteers and in patients with T2DM. Having found that T2DM
is associated with a significant increase in LL-37, we have
evaluated the effects of the LL-37 mimetic Peptide 19-2.5 in a
HFD-induced, murine model of T2DM. Specifically, we
investigate the effects of Peptide 19-2.5 on the increase in
insulin resistance, hypercholesterolemia, steatohepatitis and
proteinuria (microalbuminuria) caused by HFD and use both
molecular and metabolomics approaches to gain a better insight
into its mechanism of action.METHODS
Ethical Statement
All animal protocols in this study were approved by the Animal
Use and Care Committee of Queen Mary University of London
(QMUL), in accordance with the Home Office Guidance on the
Operation of Animals (Scientific Procedure Act 1986), publishedJuly 2021 | Volume 12 | Article 701275
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and Use of Laboratory Animals of the National Research Council
and were approved by the Animal Welfare Ethics Review Board
of QMUL. All research was conducted under the U.K. home
office project license number: 70/8350. Human samples for LL-
37 determination were obtained from subjects participating in
the Progressione delle Lesioni Intimali Carotidee (PILC) project,
which has been extensively described elsewhere (16–18). Subjects
of this study were screened at the Center for the Study of
Atherosclerosis at E. Bassini Hospital (Cinisello Balsamo,
Milan, Italy) for personal and familial clinical history of T2DM
[defined according to validated criteria (19, 20) and as previously
described (21)]. The study was approved by the Scientific
Committee of the University of Milan (SEFAP/Pr.0003). An
informed consent was obtained in accordance with the
Declaration of Helsinki.
HFD-Induced, Murine Model of T2DM
Ten-week-old male C57BL/6 mice, weighing 20-30 g (Charles
River Laboratories UK Ltd, Kent, UK). Five mice were housed
together in ventilated cages (total of 20 mice), all cages were
lined with absorbent bedding material under standard
laboratory conditions. For environmental enrichment tubes
and chewing blocks were placed into each cage. All mice had
access to water ad libitum and were housed in a temperature-
controlled room (20 ± 2°C) and subjected to a 12 h light and
dark cycle. Mice were randomly selected to receive either a
normal chow diet (20% protein, 9% fat, 4% fiber and 7% simple
sugar) purchased from Labdiet® (5R58 picolab mouse diet 20)
(St Louis, Missouri, USA) or a HFD (≈ 60% energy from fat)
purchased from the laboratory animal nutrition company
TestDiet® (58Y1 diet, St Louis, Missouri, USA) for 12 weeks.
Every week, the animals were weighed, and the diet was
adapted to body weight of each mouse. After 6 weeks of
feeding mice a HFD, mice were randomly assigned to either
receive vehicle (sterile saline, 0.9% NaCl i.p.) (HFD+Veh, n=20)
or the drug treatment, Peptide 19-2.5 (HFD+Pep2.5, n=20) (10
mg/kg x day i.p in vehicle) for 5 days per week from the end of
week 6 until the end of the experiment at week 12. Chow-fed
mice remained on the chow diet and received vehicle (sterile
saline, 0.9% NaCl i.p.) from the end of week 6 until the end of
the experiment at week 12.
OGTT
An OGTT was performed after a fasting period of 6 h in all mice
at week 6 and 12 (i.e. before intervention and after intervention).
Glucose was administered at a concentration of 2 g/kg body
weight (bw) dissolved in drinking water and administrated by
oral gavage. Mice were placed in a restrainer and a small cut on
the side of their tail was made to collect blood to monitor the
level of blood glucose at 0, 15, 30, 45, 60, 90 and 120 min from the
administration of glucose using a glucose analyzer (Accu-Chek
Compact System, Roche Diagnostics, Basel, Switzerland).
Assessment of Renal Function
At week 12, mice were individually placed in metabolic cages
with free access to food and water for 24 h to collect urineFrontiers in Immunology | www.frontiersin.org 3samples. Urine volume (urine output) was measured at the end
of the 24 h. Urine creatinine was measured in a blinded fashion
by a commercial veterinary testing laboratory (MRC Harwell
Institute, Oxfordshire, UK).
Calculating Albumin to Creatinine Ratio





Equation 1. Equation for ACR. ACR is calculated using,
urine albumin (mg/dL) and urine creatinine (mg/dL).
ELISA
Commercially available mouse albumin ELISA Kits as per
manufactures instructions (Cambridge Bioscience, Cambridge),
were used to measure urinary albumin according to the
manufacture’s instruction. The absorbance read on ELISA
plate reader at 450 nm using a spectrofluorometer (Tecan
Infinite M200 Pro, Tecan, Austria).
Western Blot Analysis
Immunoblot analyses of liver tissues were carried out using a
semi-quantitative western blotting. To assess the degree of
phosphorylation of inhibitor of kappa beta kinase (IKK) a/b at
Ser176/180, the phosphorylation of IĸBa at Ser32/36, the
translocation of the nuclear factor kappa light chain enhancer
of activated B cells (NF-ĸB) p65 subunit (RelA) to the nucleus
and the inducible nitric oxide synthase (iNOS) expression. Also,
we have evaluated the assembly and activation of the NOD-,
LRR- and pyrin domain-containing protein 3 (NLRP3)
inflammasome, including activation of caspase-1. The
phosphorylation on Ser307 of insulin receptor substrate 1 (IRS-
1) and the phosphorylation on Ser473 of protein kinase B (Akt).
Levels of CD36 expression and the degree of phosphorylation of
extracellular signal-regulated kinases 1 and 2 (ERK1/2) at the
Thr202/Tyr204 and Thr185/Tyr187 respectively, were also evaluated
in liver samples.
Antibodies were purchased from Cell Signaling Technology,
if not stated. The antibody used were (1:1000): rabbit anti-Ser307
IRS-1, mouse anti-total IRS-1, mouse anti-Ser473 Akt, rabbit anti-
total Akt, rabbit anti-Ser176/180-IKKa/b, rabbit anti-total IKKa/
b, mouse anti-Ser32/36-IkBa, mouse anti-total IĸBa, rabbit anti-
NFĸB p65, rabbit anti-iNOS, anti-tubulin (Abcam), rabbit anti
NLRP3 inflammasome (Abcam), mouse anti-caspase 1 (p20)
(Adipogen), Anti-CD36 (Abcam), rabbit anti-phospho-p44/42
MAPK (ERK1/2), rabbit anti-total p44/42 MAPK (ERK1/2),
Anti-b-actin (Sigma-Aldrich, Inc).
Mouse liver tissue weighing 30 mg to prepare the extractions
(total and/or cytosol/nucleus extractions), standardized loading
50mg of protein into the well of the gel for each sample. In cold
conditions (at 4°C) a 10-time dilution with homogenization
buffer (HB:20mM Hepes-KOH pH 7.9; 1mM MgCl 2; 0.5mM
EDTA; 1mM EGTA;1% NP-40 (or TRITON-X 100) were used to
bring to 100 ml in bi-distilled water and just before use 1ul/mlJuly 2021 | Volume 12 | Article 701275
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sample to obtain the total extraction protein content. For
cytosolic protein extraction, the homogenate was centrifuged
(at 1320g, 5 min, 4°C). To obtain the cytosolic fraction the
supernatants were removed and centrifuged (at 16125g, 40 min,
4°C). The pellet was discarded, and supernatant was kept at
-80°C for cytosolic protein analysis. The first pelleted nuclei were
re-suspended in extraction buffer (EB: 20mM Hepes-KOH pH
7.9; 1.5mM MgCl 2; 0.2mM EDTA; 1mM EGTA; 20% Glycerol;
420mM NaCl bring to 50 ml in bi-distilled water and just before
use were added: 1ul/ml DTT; 0.5mM PMSF; 1ul/ml PIC) at
concentration 1/3 compared to the HB) and kept in ice for
30 min, vortexing occasionally, before being centrifuged (at
16125g, 20 min, 4°C). The resulting supernatant was kept at
-80°C for nuclear protein analysis later. Both cytosolic/nuclear
fraction protein content were determined using bicinchoninic
acid (BCA) protein assay following manufacturer’s directions
(Therma Fisher Scientific, Rockford, IL, USA). Proteins were
separated by gel electrophoresis using 8% sodium dodecyl
sulphate-polyacrylamide (SDS-PAGE) then transferred into a
Polyvinyldenedifluoride (PVDF) membrane, blocked using 10%
milk solution in tris-buffered saline with 0.1% Tween 20
detergent (TBST) then the membrane was incubated with a
primary antibody (1:1000) in TBS1X at 4°C. The next day, the
blots were washed 3 times for 15 min and incubated with HRP-
conjugated anti-rabbit or anti-mouse secondary antibody diluted
1:10,000 in 5% blocking solution at room temperature for
30 min. Then the membranes were washed 3 times for 15 min
and the protein bands were visualized using enhanced
chemiluminescence (ECL) detection system. Bands analysis
was performed using densitometric Gel pro analyzer 4.5, 2000
software (Media Cybernetics, Silver Spring, MD, USA). Results
were then adjusted against corresponding chow data.
Organ and Blood Collection
At the end of the experiment mice were anaesthetized with
isoflurane (3%) delivered in oxygen (1 L/min). They were then
sacrificed by terminal cardiac puncture and exsanguination
(removal of blood) with a G25 needle. Approximately 0.7 ml of
blood was collected from each mouse and decanted immediately
into 1.3 ml serum gel tubes (Sarstedt, Nümbrecht, Germany). All
organs were collected and snap frozen in liquid nitrogen and were
stored at -80°C. A section of the kidney and liver were placed in 2-
methylbutane and then transferred to liquid nitrogen and stored at
-80°C. A section of the kidney and liver were fixed in formalin for
48 h and was then transferred to 70% ethanol for long-term storage.
The rest of the organ collected and placed in liquid nitrogen and
were stored at -80°C. Blood serum was isolated after being
centrifuged for 3 min at 9900 rpm, snap frozen in liquid nitrogen
and stored at -80°C. 100 ml of serum samples were then analyzed in
a blinded fashion by a commercial veterinary testing laboratory
(MRCHarwell Institute, Oxfordshire, UK) to evaluate the following
biomarker: total cholesterol, triglycerides, glucose (non-fasting) and
alanine aminotransaminase (ALT).Frontiers in Immunology | www.frontiersin.org 4Histological Analysis
Oil Red O Staining
Oil Red O staining was used for the visualization of fat in liver
samples. Frozen liver samples (using 2-methyl butane) were
embedded in optimal cutting temperature compound (OCT),
and cut into 10 mm sections. Frozen liver sections were left out
for 10 min to bring to room temperature. For 5 min, the sections
were fixed in 10% neutral buffered formaldehyde, followed by the
samples being rinsed thoroughly with running tap water.
Sections were then saturated with Oil Red O (1% w/v,60%
isopropyl alcohol) (Sigma-Aldrich, Inc., St. Louis, Missouri,
USA) and left to incubate for 15 min, then washed twice with
60% isopropyl alcohol solution, followed by being rinsed in
distilled water. For 2 min, sections were then stained with
Mayer’s hematoxylin, followed by blue in running tap water.
Using coverslips, the sections were mounted using aqueous
glycergel mounting medium (Dako, Cambridge, UK).
Picro-Sirius Red Staining
Picro-Sirius Red staining was used for the visualization of collagen
in liver samples. Samples were embedded in paraffin and cut into 4
mm sections. Liver sections were deparaffinized by washing twice in
xylene for 5 min, then rehydrated by washing in ethanol with
decreasing concentrations (100%, 95%, 90%, 80% and 70%) for
5 min. Sections were then washed in distilled water for 5 min. Picro-
Sirius stain (Abcam®, Cambridge, UK), was then covered
completely over the sections and incubated in the dark for
60 min. Slides were then rinsed quickly in two changes of 0.5%
acetic acid solution. Slides were then dehydrated by being rinsed in
two changes of absolute alcohol (100% ethanol) for 10 min. Slides
were cleared with d-limonene (national diagnostic®, Nottingham,
UK) and mounted in synthetic resin (distyrene, plasticizer and
xylene (DPX) mountant) using coverslips.
Slides from both Oil Red O and Picro-Sirius Red were
scanned using a NanoZoomer Digital Pathology Scanner
2.0HT (Hamamatsu Photonics K.K, Hamamatsu, Japan) to
obtain high-resolution images for analysis. Ten fields were then
selected from each image randomly at 40x magnification to
quantify lipids from Oil Red O staining and collagen from
Picro-Sirius Red staining in the liver were analyzed using the
NDP viewer software. The percentage of fat deposition and
collagen in the liver were calculated using the ImageJ software
version 3.3.2.
LL-37 Measurement
A commercial human LL-37 ELISA kit (#MBS2512823;
MyBioSource, San Diego, California, USA) was used to analyze
the concentration of LL-37 in healthy subjects and patients with
T2DM (Table S1). According to the detection range 1.563-100
ng/ml of the ELISA kit the samples were diluted 1:20 in sample
diluent. The measurement was performed in accordance with the
manufacturer’s instructions. The 332 optical density was
measured at 450 nm using iMark™ Microplate Absorbance
Reader (Bio-Rad Laboratories, Inc).July 2021 | Volume 12 | Article 701275
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Cytokines, chemokines and growth factors were quantified in
murine serum samples using Bio-Plex Pro™ Mouse Chemokine
31-Plex panel assay (Bio-Rad Laboratories, Inc., Hercules,
California, USA). The cytokines IL−2, -6, −10, −16, CCL2, -5.
The chemokines CXCL1, CX3CL1, -12 – 13 -16, and the growth
factor GM-CSF were measured according to the manufacturer’s
instructions. Data was acquired on Bio-Plex® 200 system (Bio-
Rad Laboratories, Inc).
Metabolomic Analysis
Metabolites were analyzed by liquid chromatography coupled to
triple quadrupole mass spectrometry (LC-MS/MS) using a high-
performance liquid chromatography (HPLC) system (Prominence
series) with an inert kit and the triple quadrupole mass spectrometer
LCMS-8050, both from Shimadzu Deutschland GmbH (Duisburg,
Germany). Samples were then analyzed with the sphingosine-1-
phosphate (S1P)/sphingosine method and the supplied method
packages “primary metabolites”, “phospholipids” and “lipid
mediators” according to the manufacturer’s protocols (Shimadzu
Deutschland GmbH, Duisburg, Germany) with the following
modifications: 20 μl of serum sample were precipitated by addition
of 200 mL of methanol (LCMS-grade) in vials. Prior to processing, the
methanol was spiked with internal standard (IS) solution in a final
concentration of 9.09 mM2-morpholinoethanesulfonic acid (Sigma-
Aldrich, Inc.), 136.36 nM lysophosphatidylcholine (17:0) (Sigma-
Aldrich, Inc.) and 136.36 nM sphingosine (17:0) (Cayman
Chemical, Michigan, USA). After 4 days of incubation the
supernatant was analyzed at -80°C and centrifugation at 14,000 g
for 10 min at 4°C. Primary metabolites were analyzed using the
HPLC Column Discovery® HS F5, 3 μm, 150 mm x 2.1 mm
(Sigma-Aldrich, Inc). For phospholipids and lipid mediators the
2.1 x 150 mm 2.6 μm particle size C8 Kinetex LC Column
(Phenomenex, Inc., Torrance, USA) was used. Sphingosine-1-
phosphate and sphingosine were separated using a MultoHigh
100 RP 18-3μ 60 x 2 mm column (Chromatography Service
GmbH, Langerwehe, Germany) with intermittent runs for
equilibration. Mass spectrometric detection was performed by
multiple reactions monitoring (MRM) after injection of 10 μl
sample, unless stated otherwise. Further information on HPLC
programs and solvents (Table S2), LCMS-8050 settings (Table S3),
and recorded mass transitions of identified significantly changed
analytes (Tables S4–S7). Metabolome primary data were analyzed
and further processed with LabSolutions 5.91 and LabSolutions
Insight 3.10 (Shimadzu Deutschland GmbH).
Statistical Analysis
All data were analyzed using GraphPad Prism 7.0 (GraphPad
Software, San Diego, California, USA). All data in both text and
figures are expressed as mean ± standard error of the mean
(SEM) of n observations, where n represents the number of
animals studied. Data was then assessed using One-way or Two-
way ANOVA, followed by Bonferroni’s post-hoc or Kruskal-
Wallis test and Dunn’s multiple comparisons test according toFrontiers in Immunology | www.frontiersin.org 5the data distribution profile. A two-tailed unpaired student t-test
was performed when the mean of two experimental groups were
compared. P< 0.05 were considered to be statistically significant.
Statistical outliers were detected by outlier test to analyze the
statistical significance of the LL-37 concentration in patients and
sample valves were interpolated from 4PL regression standard
curve. Area under the curve was used to analyze the OGTT test
results. Metabolome data were analyzed by calculating area ratios
for each analyte by dividing peak area of each analyte by peak
area of the related IS. Data analysis for metabolome data was
performed as follows: readings below detection level were set to
half of detection level for each analyte separately. Metabolome
data was log2 transformed and normalized by subtracting
median metabolite abundance per sample from all abundances
of each sample. Normalization was carried out separately for
primary metabolites (included S1P and sphingosine),
phospholipids and lipid mediators. Z scores were calculated
using mean and standard deviation of all samples. Contrasts
were analysed pairwise between all three sample groups (chow,
HFD+Veh, HFD+Pep2.5) by unpaired t-tests. P-values were
Benjamini Hochberg adjusted (22). Data analysis was carried
out using R version 3.4.4 (R Core Team 2018). R: A Language
and Environment for Statistical Computing. Vienna: R
Foundation for Statistical Computing’, available online at:
https://www.R-project.org/.RESULTS
LL-37 Is Increased in Patients With T2DM
When compared to healthy subjects, LL-37 concentration was
significantly higher in patients with T2DM (Figure 1).
Treatment With Peptide 19-2.5 Attenuates
Weight Gain and Insulin Resistance in
High-Fat Diet-Fed Mice and Improves
Insulin Signaling in the Liver
When compared to chow-fed mice, HFD-fed mice treated with
vehicle had a higher body weight throughout the experiment
(Figure 2A). However, when compared to HFD-fed mice treated
with vehicle, HFD-fed mice treated with Peptide 19-2.5,
significantly attenuated the increase in weight gain from the
start of drug treatment (from the end of week 6) until the end of
the experiment (week 12) (Figure 2A), indicating the
effectiveness of Pe2.5 to attenuate the increase in body weight
caused feeding mice a HFD. Treatment of HFD-mice with
Peptide 19-2.5 (week 6-12) caused a transient reduction in
calorie and food intake (at week 8), but neither calorie nor
food intake were reduced at the end of the experiment (when
compared to HFD-mice treated with vehicle; Figure S1).
When compared to chow-fed mice, HFD-fed mice treated
with vehicle challenged with an oral dose of glucose developed a
significant change in OGTT by 6-weeks of being fed a HFD
(Figure S2), and this further declined by the end of theJuly 2021 | Volume 12 | Article 701275
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associated with significantly elevated levels of non-fasting blood
glucose level by week 12 (Figure 2B) indicating that feeding mice
a HFD effectively caused the onset of hyperglycemia. However,
HFD-fed mice treated with Peptide 19-2.5 markedly reduced (i)
the impairment in OGTT (Figures 2C, D) and the (ii) non-
fasting blood glucose levels by week 12 (Figure 2B). To gain a
better insight into the potential mechanism underlying the
reduced insulin resistance after HFD feeding, we investigated
the effects of Peptide 19-2.5 on the insulin signaling pathway in
the liver. HFD-fed mice treated with vehicle exhibited a
significant increase in the phosphorylation on Ser307 of IRS-1
(Figure 2E), hence resulting in a reduction in the
phosphorylation of the downstream mediator Akt on Ser473
(Figure 2F), indicating an impairment in insulin signaling. In
contrast, treatment with Pep9-2.5 prevented the increase in the
phosphorylation on Ser307 of IRS-1 and hence attenuated the
decline in the phosphorylation of Akt on Ser473, hence, Peptide
19-2.5 effectively improved insulin signaling and glycemic
regulation in HFD-fed mice (Figures 2E, F).
Treatment With Peptide 19-2.5 Attenuates
Hypercholesterolemia in High-Fat
Diet-Fed Mice
When compared to chow-fed mice, HFD-fed mice treated with
vehicle showed a significant increase in serum total cholesterol
(Figure 3A) and a trend of an increase, although not significant
in serum triglycerides (Figure 3B) suggesting that feeding mice a
HFD causes hypercholesterolemia. When compared to HFD-fed
mice treated with vehicle, HFD-fed mice treated with Peptide 19-
2.5, showed a significant reduction in serum total cholesterol
(Figure 3A) and a trend of a small, but not significant reductionFrontiers in Immunology | www.frontiersin.org 6in serum triglycerides (Figure 3B), demonstrating the ability of
Peptide 19-2.5 to attenuate the development of hypercholesterolemia.
Treatment With Peptide 19-2.5 Attenuates
Microalbuminuria in High-Fat
Diet-Fed Mice
ACR was calculated to study the effect of proteinuria in HFD-fed
mice, which is the hallmark symptom of diabetic nephropathy
(23, 24). When compared to chow-fed mice, HFD-fed mice
treated with vehicle demonstrated a significant increase in
ACR by the end of the experiment, indicating the development
of microalbuminuria, which was significantly attenuated by the
treatment with Peptide 19-2.5 in HFD-fed mice (Figure 4).
Treatment With Peptide 19-2.5 Abolishes
Steatohepatitis and Liver Injury but Does
Not Affect Collagen Deposition in High-Fat
Diet-Fed Mice
HFD feeding results in the development of hepatosteatosis (25).
When compared to chow-fed mice, HFD-fed mice treated with
vehicle showed a significant increase in the percentage of lipids
stained with Oil Red O in the liver (Figure 7B). However,
treatment with Peptide 19-2.5 in HFD-fed mice resulted in a
significant reduction in fat deposition in the liver (Figure 5B)
and, hence, a reduction in steatosis. When compared to chow-fed
mice, HFD-fed mice treated with vehicle showed a significant
increase in the percentage of collagen fibers in the liver
(Figure 5C), while treatment with Peptide 19-2.5 in HFD-fed
mice showed no significant effect on collagen deposition
(Figure 5C). HFD-fed mice exhibited an increase in liver
weight and a significant increase in serum levels of ALT (liver
injury) (Figure 5D). Most notably, treatment of HFD-mice withFIGURE 1 | LL-37 serum levels in healthy subjects and patients with T2DM. Serum concentrations of LL-37 were assessed in healthy subjects and patients with
T2DM. Data were analyzed by unpaired t-test (two-tailed). Data are expressed as mean ± SEM; healthy subjects (n = 10), T2DM patients (n = 12). *P < 0.05 vs.
healthy subjects.July 2021 | Volume 12 | Article 701275
Mohammad et al. Peptide 19-2.5 Attenuates HFD-Induced T2DMPeptide 19-2.5 reduced the increase in liver weight and liver
injury caused by the HFD (Figures 5A, D). Hence, feeding mice
a HFD resulted in the development of a larger fatty liver
(steatosis) associated with liver injury, both of which were
abolished by treatment of Peptide 19-2.5 in HFD-fed mice.Frontiers in Immunology | www.frontiersin.org 7Treatment With Peptide 19-2.5 Reduces
Liver Inflammation in High-Fat
Diet-Fed Mice
Using western blot analysis, the NF-ĸB signaling pathway and




FIGURE 2 | Peptide 19-2.5 ameliorated glycemic regulations by the improvement of insulin signaling in HFD-fed mice. (A) Body weight was measured once a week
for 12 weeks (g). (B) Non-fasting glucose levels were measured at week 12 (mg/dl) (C) Oral glucose tolerance (OGTT) was assessed over 120 min, after receiving an
oral dose of glucose at week 12 (mg/dl) and the (D) area under the curve (AUC) of OGTT was calculated for respective groups and used for statistical analysis (au).
Data are expressed as mean ± SEM; n = 20 per group, n = 10 for non-fasting glucose levels. *P < 0.05, **P < 0.01, ***P < 0.001, and ****P < 0.0001 vs. HFD +
Veh. (E) Densitometric analysis of the bands is expressed as relative optical density (O.D.) for the phosphorylation on Ser307 IRS-1in the liver and normalized to total
IRS-1 and (F) for the phosphorylation on Ser473 of Akt in the liver normalized to total Akt. Data was analyzed by one-way ANOVA, with Bonferroni post-hoc test.
Data are expressed as mean ± SEM; chow (n = 5), HFD+Veh (n = 6), HFD+Pep2.5 (n = 6). **P < 0.01 and ***P < 0.001 vs. HFD+Veh.July 2021 | Volume 12 | Article 701275
Mohammad et al. Peptide 19-2.5 Attenuates HFD-Induced T2DMthe liver. Both of which are key drivers of liver inflammation
associated with steatohepatitis.
When compared to chow-fed mice, HFD-fed mice treated with
vehicle showed a significant increase in the phosphorylation of
IKKa/b at Ser176/180, in the phosphorylation of IĸBa at Ser32/36, in
the translocation of NF-ĸB subunit p65 to the nucleus and in iNOS
expression in the liver, indicating that feeding mice a HFD causes
the activation of the NF-ĸB signaling pathway (Figures 6A–D).
Administration of Peptide 19-2.5 in HFD-fed mice significantly
attenuated the degree of phosphorylation of IKKa/b at Ser176/180,
the phosphorylation of IĸBa at Ser32/36, translocation of the p65
subunit of NF-ĸB to the nucleus and iNOS expression in the liver
(Figures 8A–D), indicating the ability of Peptide 19-2.5 to
effectively inhibit the NF-ĸB signaling pathway in the liver.
When compared to chow-fed mice, HFD-fed mice treated
with vehicle showed a significant increase in the expression of the
inflammasome, NLRP3 and cleavage of pro-caspase-1 to
caspase-1 in the liver (Figures 6E, F). However, the activationFrontiers in Immunology | www.frontiersin.org 8of assembly of the NLPR3 inflammasome was effectively
attenuated by the treatment with Peptide 19-2.5 in HFD-fed
mice (Figures 6E, F).
Hence, together demonstrates the ability of Peptide 19-2.5 to
attenuate the activation of NF-ĸB as well as the activation and
assembly of the NLRP3 inflammasome. Therefore, reducing liver
inflammation in HFD-fed mice.Treatment With Peptide 19-2.5 Reduces
the Expression of CD36 and the Activation
of ERK in the Liver of High-Fat
Diet-Fed Mice
When compared to chow-fed mice, HFD-fed mice treated with
vehicle showed a significant increase in the expression of CD36
and the phosphorylation of ERK1/2 (Figure 7). However,
treatment with Peptide 19-2.5 inhibited the expression of
CD36 and the phosphorylation of ERK2, with a small but notA B
FIGURE 3 | Peptide 19-2.5 attenuates hypercholesterolemia in HFD-fed mice. Serum samples were collected at the end of the experiment to measure (A) total
cholesterol (mg/dl) and (B) triglycerides (mg/dl). Data was analyzed by one-way ANOVA, with Bonferroni post-hoc test. Data are expressed as mean ± SEM; n = 10
per group. **P < 0.01 and ****P < 0.0001 vs. HFD + Veh.FIGURE 4 | Peptide 19-2.5 attenuates the development of microalbuminuria in HFD-fed mice. At week 12 urine was collected to calculate the albumin to creatinine
ratio (ACR) (mg/dl). Data was analyzed by one-way ANOVA, with Bonferroni’s post-hoc test. Data are expressed as mean ± SEM; n = 10 per group. ****P < 0.0001
vs. HFD+Veh.July 2021 | Volume 12 | Article 701275
Mohammad et al. Peptide 19-2.5 Attenuates HFD-Induced T2DMsignificant reduction of the phosphorylation of ERK1 in the liver
in HFD-fed mice (Figure 7).
Effect of Peptide 19-2.5 Treatment on
Cytokine, Chemokine, and Growth Factor
Analysis in High-Fat-Diet-Fed Mice
HFD-fed mice treated with peptide 19-2.5, showed no significant
differences in the levels of the following cytokines: IL-6, IL-10,
IL-16, IL-2, KC/CXCL1, MCP-1/CCL2 and Rantes/CCL5. The
following chemokines: Fractalkine/CX3CL1, BCA-1/CXCL13,
SDF-1a/CXCL12, SCYB16/CXCL16 and the growth factor,
GM-CSF (Figures 8A–L).
Treatment With Peptide 19-2.5 Enhances
Levels of Carnitine in High-Fat-Diet
Fed Mice
Using a targeted metabolomic approach, we studied the effect of
Peptide 19-2.5 on metabolite levels in the serum of HFD-fed mice.
The detected 217 analytes were subdivided in 49 primary
metabolites, 146 phospholipids, 20 lipid mediators, sphingosine-1-
phophate and sphingosine. Log2 fold change heatmaps showed all
detected analytes (Figures 9A and S6, S7). Significantly changed
analytes were identified and analyzed via dot plot (Figure 9B),Frontiers in Immunology | www.frontiersin.org 9hierarchical clustered z score heatmaps (Figures S3–S5) and
volcano plots (Figures 9C–E and S8, S9). Detailed statistical
information of the detectable analytes is shown in
Supplementary Data.
The log2 fold change heatmap illustrates all detected primary
metabolites, sphingosine-1-phosphate and sphingosine
(Figure 9A). Within these metabolites only carnitine showed a
significant decrease in mice-fed a HFD (treated with vehicle)
compared with mice-fed a chow diet as well as a significant
increase in the HFD+Pep2.5 group compared with the HFD+Veh
group (Figure 9B). This indicates an involvement of Peptide 19-2.5
in the restoring of carnitine level in mice-fed a HFD. Volcano plot
analysis highlights significantly different analytes with at least
twofold changed primary metabolites. The comparison of primary
metabolites between the chow group and the HFD+Veh group
showed that 5 primary metabolites were significantly reduced in the
HFD+Veh group (Figure 9C). Seven primary metabolites were
significantly decreased and 3 were significantly increased in the
HFD+Pep2.5 group compared with chow group (Figure 9D). The
group comparison between HFD+Pep2.5 and HFD+Veh identified
1 primary metabolite with a significant decrease and 2 primary





FIGURE 5 | Peptide 19-2.5 abolishes steatohepatitis in HFD-fed mice. (A) Liver images of mice immediately after being culled and the liver weights (g). (B) Images
of hepatic lipid deposition using Oil Red O staining and quantified as percentage of fat deposition (%). (C) Images of hepatic collagen deposition using Picro-Sirius
Red stain to quantify percentage collagen deposition (%). Insert images are 40x magnification digital zoom and scale bars measure 50µm. (D) Serum ALT (U/L).
Data were analyzed by one-way ANOVA, with Bonferroni’s post-hoc test. Data are expressed as mean ± SEM; n = 20 per group. **P < 0.01 and ****P < 0.0001
vs. HFD+Veh.July 2021 | Volume 12 | Article 701275
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We have discovered that patients with T2DM have elevated
levels of the endogenous, AMP LL-37. It is not clear whether this
increase in LL-37 contributes to the pathophysiology of the
metabolic syndrome or T2DM or whether this increase is a
defense mechanism to protect us from the consequences of
metabolic endotoxemia (see Introduction). If the latter is the
case, then AMPs may be able to reduce the degree of metabolic
endotoxemia and, hence, some of the pathology associated with
T2DM. It should be noted that LL-37 itself is toxic to human T-
lymphocytes and human leukocytes (27). LL-37, has also been
shown to be toxic in neonatal rat model of septic shock (28) and,
hence, cannot be used as a therapeutic remedy. Over the past
years, significant efforts have been made to develop synthetic
AMPs which do not have toxic effects. One of these peptides,
Peptide 19-2.5, binds to and inactivates LPS and, indeed, other
damage-associated molecular patters (DAMPs) including
heparan sulphate and high mobility group protein B1
(HMGB1) (29). Peptide 19-2.5 is not toxic in cellular assays
(e.g. Jurkat cells, human macrophages, human red blood cells)
(14, 30). The maximal tolerated dose (MTD) of Peptide 19-2.5 in
a 14-day repeated dosing study in rats is greater than 20 mg/kg/
day (K Brandenburg, personal communication).Frontiers in Immunology | www.frontiersin.org 10As Peptide 19-2.5 has a favorable toxicological profile when
compared to LL-37, we have investigated whether Peptide 19-2.5
affects the metabolic/diabetic phenotype in a HFD-induced
model of obesity and T2DM. We report here for the first time
that Peptide 19-2.5 reduces the insulin resistance,
hypercholesterolemia, steatohepatitis and microalbuminuria
caused by feeding mice a HFD. Peptide 19-2.5 also inhibited
the activation of NF-kB and the NLRP3 inflammasome and
reduced the expression of CD36 as well as ERK1/2 in the liver.
HFD-fed mice showed a progressive increase in body weight
indicating the development of obesity. Indeed, it is well known
that even shorter periods of HFD (3 weeks) result in insulin
resistance and hyperglycemia in mice (31). In our study, mice fed
a HFD for 12 weeks developed severe insulin resistance, as
indicated by an increase in the impairment of glucose
tolerance [measured by the (OGTT) and an increase in non-
fasting blood glucose levels at the end of the experiment (week
12), HFD also caused a significant increase in the
phosphorylation of Ser307 of IRS-1 (a marker of insulin
resistance), which impairs the ability of IRS-1 to activate the
phosphatidylinositol 3-kinase-dependent downstream pathway
(32). Hence, in our study there was a decline in the
phosphorylation of the downstream mediator Akt on Ser473 in
HFD-fed mice treated with vehicle. The phosphorylation ofA B
D E F
C
FIGURE 6 | Peptide 19-2.5 reduces liver inflammation via the inhibition of NF-kB signaling pathway and the activation of NLRP3 inflammasome in the liver of HFD-
fed mice. Liver samples were collected at the end of the experiment and the NF-kB signaling pathway, as well as the activation of the NLRP3 inflammasome were
assessed. Densitometry analysis of the bands is expressed as relative optical density (O.D.) of the (A) phosphorylation of IKKa/b at Ser178/180 corrected for the
corresponding total IKKa/b content and normalized using the related chow band; (B) phosphorylation of IĸBa at Ser32/36 corrected for the corresponding total IĸBa
content and normalized using the related chow band; (C) NF-kB p65 subunit levels in both, cytosolic and nuclear fractions expressed as a nucleus/cytosol ratio
normalized using the related chow bands; (D) inducible nitric oxide synthase (iNOS) expression corrected for the corresponding tubulin band. (E) NLRP3 activation,
corrected against tubulin and normalized using the related chow bands and the (F) proteolytic cleavage of pro-caspase-1 to activated caspase-1 and normalized
using the related chow band. Data were analyzed by one-way ANOVA, with Bonferroni’s post-hoc test. Data are expressed as mean ± SEM; chow (n = 5), HFD
+Veh (n = 6), HFD+Pep2.5 (n = 6). ***P< 0.001, and ****P < 0.0001 vs. HFD+Veh.July 2021 | Volume 12 | Article 701275
Mohammad et al. Peptide 19-2.5 Attenuates HFD-Induced T2DMSer307 on IRS-1 is also associated with the activation of IKK
complex (32). However, the contribution of this in the
development of insulin resistance is not well understood. We
report here that HFD-fed mice treated with Peptide 19-2.5
resulted in the improvement of glycemic control secondary to
the restoration of the IRS-1 signaling pathway in the liver.
One of the hallmarks of diabetic nephropathy in mice and
man is the development of (micro) albuminuria (33–35). The
elevation in urine albumin, termed microalbuminuria is a result
of renal injury and hyperfiltration and is the first sign of diabetic
nephropathy which can lead to an increased risk of
cardiovascular disease (36). Hyperglycemia is the key driver of
the microvascular injury in diabetes, as excess glucose drives the
formation of reactive oxygen species (ROS), which in turn
activate protein kinase C (PKC) and NF-kB leading to
increased expression of vascular endothelial growth factor
(VEGF) and vascular permeability (37). ACR is a reliable
measure of the development of microalbuminuria (23, 24). We
report here that treatment of mice challenged with a HFD and
treated with Peptide 19-2.5 (from the end of week 6 to week 12)
largely attenuated the microalbuminuria caused by HFD.
The most striking finding of our study, however, is that HFD-
fed mice treated with Peptide 19-2.5 abolished steatohepatitis.
Exposure of mice to a HFD for 12 weeks resulted in an increase
in liver weight secondary to a very dramatic increase in hepatic
fat deposition (measured using Oil Red O staining). Indeed, an
increase in fat deposition in the liver in response to a HFD occurs
as early as 4 weeks in mice (38). This deposition of fat drives
steatohepatitis resulting in liver injury (measured as an increase
in serum ALT). Most notably, treatment of mice subjected to a
HFD for 12 weeks with Peptide 19-2.5 abolished both theFrontiers in Immunology | www.frontiersin.org 11increase in liver weight and the degree of fat deposition in
mice challenged with a HFD.
The deposition of excessive amounts of fat caused by HFD in
the liver was associated with a marked activation of the NF-ĸB
signaling pathway as well as the assembly and expression of the
NLRP3 inflammasome, both of which are key drivers of liver
inflammation associated with steatohepatitis (39, 40). NF-kB, is a
key transcription regulator of the inflammatory response and the
activity of NF-kB is regulated by binding to inhibitory units of
the IkB proteins, including IkBa, Ikb and IkBϵ. IkBa inactivates
NF-kB by masking the nuclear localization site of the NF-kB
protein and sequestering the inactive NF-kB complex in the
cytoplasm. Phosphorylation of IkBa by IKK marks the
degradation and the dissociation of IkBa from NF-kB, thus
allowing the activated NF-kB to translocate to the nucleus and
activate target genes. There is good evidence that NF-kB is
essential in regulating the inflammatory signaling pathway in
the liver and important for regulating functions in the
hepatocytes and Kupffer cells (39, 41, 42), while inhibition of
NF-kB reduces the degree of liver injury (43). We report here
that mice challenged with a HFD for 12 weeks showed an
increase in phosphorylation (a) of IKKa/b on Ser178/180 and
(b) of IkBa at Ser32/36, (c) in the translocation of NF-kB subunit
p65 to the nucleus and (d) the expression of the NF-kB-
dependent proinflammatory protein, iNOS in the liver, all of
which were attenuated effectively by treatment with Peptide 19-
2.5. Indeed, iNOS is widely expressed in many insulin-sensitive
tissues/organs including adipose tissue and liver (44). The
expression of iNOS is increased in the liver of diabetic mice
leading to an impairment in insulin signaling and hyperglycemia,
while iNOS inhibition (L-NIL) improves insulin signaling (liver)A B
FIGURE 7 | Peptide 19-2.5 reduces CD36 expression and the activation of ERK in the liver of HFD-fed mice. Liver samples were collected at the end of the
experiment and the expression of CD36 and the phosphorylation of ERK1/2 were assessed. Densitometry analysis of the bands is expressed as relative optical
density (O.D.) of (A) CD36 expression, corrected against tubulin and normalized using the related chow bands; (B) phosphorylation of ERK1/2 corrected to the
corresponding total ERK1/2 content and normalized using the related chow band. Data was analyzed by one-way ANOVA, with Bonferroni post-hoc test. Data are
expressed as mean ± SEM; n = 8 per group. ***P < 0.001 and ****P < 0.0001 vs. HFD+VehJuly 2021 | Volume 12 | Article 701275
Mohammad et al. Peptide 19-2.5 Attenuates HFD-Induced T2DMand prevents hyperglycemia (44). Most notably, iNOS knock out
mice subjected to a HFD develop less insulin-resistance than
their wild-type litter mates (45). Thus, prevention of the
expression of iNOS (secondary to prevention of the activation
of NF-kB) may well have contributed to the beneficial effects of
Peptide 19-2.5 observed here.
Activation of the NLRP3 inflammasome in hepatocytes plays
a pivotal role in liver disease, while inhibition of the assembly
and/or activation of the NLRP3 inflammasome reduces liver
inflammation and injury (46, 47). Inflammasomes are cytosolicFrontiers in Immunology | www.frontiersin.org 12protein complexes that mediate host immune responses to
infection and cellular damage by sensing danger signals via
NOD-like receptors, NLRs. The assembly of an inflammasome
causes the proteolytic cleavage of procaspase-1 into the active
caspase-1. The active caspase-1 is important for converting pro-
IL-1b into the active IL-1b and the formation of IL-18 amplifying
inflammation (48). Here, we demonstrated that Peptide 19-2.5
attenuated the formation of the NLRP3 complex and inhibited
the cleavage of pro-caspase 1 to the active caspase caused by HFD





FIGURE 8 | Effect of peptide 19-2.5 on cytokine, chemokine and growth factor analysis in HFD-fed mice. Bio-plex pro mouse chemokine assay was performed
on serum samples of mice collected at the end of the experiment. To measure the following chemokines, cytokines and growth factor: (A) IL-6 (pg/ml), (B) IL-10
(pg/ml), (C) IL-16 (pg/ml), (D) IL-2 (pg/ml), (E) KC/CXCL1 (pg/ml), (F) MCP-1/CCL2 (pg/ml), (G) Rantes/CCL5 (pg/ml), (H) Fractalkine/CX3CL1 (pg/ml), (I) BCA-1/
CXCL13 (pg/ml), (J) SDF-1a/CXCL12 (pg/ml), (K) SCYB16/CXCL16 (pg/ml) and (L) GM-CSF (pg/ml). Data were analyzed by one-way ANOVA, followed by
Kruskal-Wallis test, Dunn’s multiple comparison test. Data are expressed as mean ± SEM; chow (n=8), HFD+Veh (n = 15), HFD+Pep2.5 (n = 11) per group.
*P < 0.05 vs. HFD+Veh.July 2021 | Volume 12 | Article 701275
Mohammad et al. Peptide 19-2.5 Attenuates HFD-Induced T2DMWhat, then, is the mechanism(s) by which Peptide 19-2.5
reduces the uptake of lipids into the liver? Steatosis is
characterized by the accumulation of excess triglycerides in
hepatocytes (49). The uptake of fatty acids from the circulation
into the liver is dependent on transporters including CD36. CD36 a
class B savage receptor which recognizes a variety of ligands
including free fatty acids, phospholipids, oxidized low-density
lipoprotein (oxLDL) and collagen and is important for fatty acid
uptake and lipid metabolism (50). CD36 is highly expressed in
many organs associated with diabetes such as the skeletal muscle,
cardiac muscle, liver and the kidney. There is good evidence that the
CD36 receptor is involved in the pathogenesis of insulin resistance
and diabetes (51), as the receptor interacts with glucose, insulin and
lipids (52). There is significant evidence that HFD causes an increase
in free fatty acids, which results in the upregulation of CD36 in the
liver, skeletal muscle, and cardiac muscle, which in turn leads to
steatosis and insulin resistance (11, 52, 53). Furthermore, an
increase in CD36 expression also positively correlates with the
development of non-alcoholic steatohepatitis (NASH) and fatty
liver (54). Most importantly, there is evidence that the upregulation
of CD36 is a key driver in the pathogenesis of steatosis.Frontiers in Immunology | www.frontiersin.org 13Indeed, hepatocyte-specific CD36 knock out mice challenged
with a HFD have a reduction in lipid uptake into the liver and,
hence, less steatosis (50). We report here that challenge of mice
with HFD leads to an increase in the expression of CD36; and
this effect is abolished in HFD-fed mice treated with Peptide 19-
2.5. We also report here that the plasma levels of the human
cathelicidin, LL-37, are elevated in patients with T2DM.
Interestingly, overexpression of LL-37 in mice prevents diet-
induced increases in CD36 expression, hepatic steatosis and
obesity (55). As Peptie 19-2.5 is a mimic of LL-37, its potential
mechanism of action in models of diet-induced obesity, NASH
and insulin resistance may be secondary to reduction of the
expression of CD36. Hence, resulting in reduced lipid uptake.
This may explain the observed reduction in weight gain, liver
steatosis and the improvement in OGTT. Overall, our findings
support the view that Peptide 19-2.5 prevents the upregulation of
CD36 which is a significant driver in the pathogenesis
of steatohepatitis.
There is good evidence that the expression of CD36 caused by
HFD is secondary to the activation of the ERK1/2 (MAPK)
pathway: Activation of ERK1/2 drives both CD36 expression andA B
D E
C
FIGURE 9 | Effect of peptide 19-2.5 administration on primary metabolites in the serum of HFD-fed mice at week 12. HFD-fed mice received either vehicle or
peptide 19-2.5. Metabolome analysis was performed on serum samples. Chow (n = 8), HFD+Veh (n = 13), HFD+Pep2.5 (n = 11). (A) Heatmap of all detected
primary metabolites. Log2 fold changes and P-values*< 0.05 are shown for all tested groupwise comparisons: HFD+Veh vs. chow, HFD+Pep2.5 vs. chow and
HFD+Pep2.5 vs. HFD+Veh. Each column represents a groupwise comparison and each row defines an analyte. Analytes were hierarchically clustered using
Ward’s minimum variance method (26) and an euclidian distance between log2 fold changes. Dendrograms provide information about distances between
clusters. Black frames show analytes with significant differences between the chow and HFD+Veh group as well as that between the HFD+Veh and HFD+Pep2.5
group. (B) Dot plot of carnitine shows restored levels in HFD-fed mice treated with peptide 19-2.5. Area ratios were calculated by dividing peak area of carnitine
by peak area of the related internal standard. Data expressed as mean ± SEM for n number of observations. *P < 0.05 and **P < 0.01 vs. HFD+Veh.
(C–E) Volcano plots of primary metabolites. Volcano plots of all tested groupwise comparisons for primary metabolites showing log2 fold changes and adjusted
P-values of groupwise comparisons. (C) HFD+Veh vs. chow, (D) HFD+Pep2.5 vs. chow and (E) HFD+Pep2.5 vs. HFD+Veh. Significantly different analytes are
depicted as black circles. Grey dots represent analytes that were not significantly different for the respective comparison. Grey dashed lines indicate absolute
log2 fold change of 1.July 2021 | Volume 12 | Article 701275
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reduces CD36 expression in hepatocytes (55). LL-37 inhibits
ERK phosphorylation in macrophages (58) and the activation of
ERK with EGF reverses both the inhibition of CD36 expression
and the lipid accumulation caused by LL-37 in adipocytes and
hepatocytes (55). We report here that Peptide 19-2.5 inhibits
both the phosphorylation of ERK1/2 as well as CD36 expression
caused by HFD in the liver. Taken together, these findings
support the view that activation of ERK1/2 in the liver of mice
subjected to a HFD drives the expression of CD36, which, in
turn, promotes lipid deposition and ultimately steatohepatitis.
The observed inhibition of ERK/1/2 phosphorylation in the liver
of HFD-mice treated with Peptide 19-2.5, on the other hand,
prevents expression of CD36, lipid deposition, liver
inflammation and injury. Thus, like LL-37, Peptide 19-2.5,
reduced CD36 expression through an ERK-dependent
mechanism, which prevents lipid deposition in the liver of
animals subjected to a HFD.
In addition to preventing the deposition of excessive fat in
the liver (by inhibiting activation of ERK1/2 and the
upregulation of CD36) and liver inflammation (by reducing
the activation of NF-kB, iNOS expression and activation of the
inflammasome), Peptide 19-2.5 may also reduce the degree of
metabolic endotoxemia associated with HFD. There is good
evidence that (a) HFD causes disruptions to tight junctions in
the gut (59) (b) HFD causes the reduction in the expression of
tight junctions (60) and (c) HFD causes the activation of NF-
kB which regulates myosin light chain kinases (MLCK), and
this increases tight junction permeability (61). Under healthy
conditions the opening and closing of paracellular junction is
tightly regulated allowing only digested proteins to pass
through. However, dysregulation of the cellular junction by
irritation from diet, stress or lack of exercise causes damage to
the intestinal cells and the junctions loosen. It is the loss of
barrier integrity that allows the translocation of LPS and
undigested food particles via the mucosa to pass through into
the bloodstream (62). This triggers an immune response
leading to low-grade inflammation, as well as steatosis,
insulin resistance and the secretion of cytokines. Endotoxins,
for example LPS are able to interact with immune cells and
adipocytes, leading to a chronic, systemic inflammation by
activating NF-kB (e.g. in the liver) which importantly
contributes to the development of met-inflammation. We
report here that Peptide 19-2.5 attenuates the degree of
phosphorylation of IKKa/b, IkBa, the translocation of NF-kB
to the nucleus and the iNOS expression in the liver. These
findings indicate that Peptide 19-2.5 may prevent the binding
of LPS to TLR4 resulting in the prevention of the activation of
NF-kB and the inflammasome. The lipid A moiety of LPS has a
cubic aggregate structure and when bound to Peptide 19-2.5 is
converted into an inactivated, multilamellar structure (14, 30).
Atomic force imaging showed morphological changes of
bacteria upon treatment with Peptide 19-2.5, with a strong
ability to agglomerate the bacteria (46). The structure of the
Peptide 19-2.5-LPS aggregate was determined using small-Frontiers in Immunology | www.frontiersin.org 14angle-x-ray scattering (SAXS) (5). Freeze-fracture electron
microscopy showed that LPS presents as a ribbon-like
structures with a length of a few hundred μm and a
thickness of 14-20 nm with varying width. In the presence of
Peptide 19-2.5, the structure changes to large and more densely
packed multilamellar aggregates (63). In the absence of Peptide
19-2.5 for peptide polymyxin B (PMB), there was no scattering
signal. However, in the presence of Peptide 19-2.5 there was
scattering between 22 nm and 25 nm and this value
corresponds to the thickness of the bacterial envelope. The
decrease in LPS bioactivity with the increased size of LPS
aggregates is due to the fact that the binding sites for
lipopolysaccharide binding protein (e.g. LBP) and CD14 are
hidden in multilamellar aggregates. Interestingly, the binding
affinity of the peptide exceeds that of other LPS-binding
proteins (e.g LBP) and prevents the binding of LPS to TLR4
(64). Although both LL-37 and synthetic AMPs, such as
Peptide 19-2.5, bind to and inactivate LPS, it should be noted
that the effect of these cationic peptides is not limited to LPS
alone, as they can also bind to lipoprotein (LP).
LP induces inflammation by activating TLR2 resulting in the
activation of a signaling cascade that drives activation of NF-kB
and, hence, the formation of many pro-inflammatory
chemokines and cytokines (65). In skin cells, the AMPs
Peptide 19-2.5 and Peptide 19-4LF inhibit the inflammatory
response that is triggered by either LPS or LP (63). Cathelicidins
are also capable of inhibiting inflammatory responses driven by
TLR2 activation by directly interacting with TLR2 ligands (66).
Using isothermal titration, LL-37 was shown to bind to
lipoteichoic acid (LTA) and LPS (67). It has been proposed
that the synthetic AMPs Peptide 19-2.5 and Peptide 19-4LF may
also inhibit intracellular signaling events as well as the
extracellular TLR2/4 signaling. This includes Peptide 19-2.5
inhibiting intracellular LPS-induced caspase-1 activation and
HMGB1. Although the mechanism is unclear this may be due
to Peptide 19-2.5 inhibiting extracellular LPS, hence preventing
the accumulation intracellularly. TLR2 is also capable of
initiating the activation of NLRP3 inflammasome (68).
Taken together, the above findings support the view that
Peptide 19-2.5 may reduce the degree of diet-induced metabolic
alterations by preventing metabolic endotoxemia. This potential
mechanism of action is much more difficult to prove, as the
determination of LPS in the blood (of the mesenteric or hepatic
circulation) is difficult for a number of reasons: The limulus
amebocyte lysate (LAL) assay is commonly used to detect
endotoxins, but false positive results in blood obtained from
animals subjected to a HFD may occur, as both triglycerides and
very low-density lipoproteins increase the sensitivity of LAL
assay, due to the direct activation of LAL. Patients with T2DM
present higher levels of serum triglycerides, hence increasing the
chance of false-positives (69). There is also a chance of false
negatives results, as LPS entering the bloodstream allows the
lipid A part of LPS to associate with the phospholipid of the
serum lipoproteins, hence this will make it difficult to detect LPS
using the LAL assay (70). These limitations are challenging toJuly 2021 | Volume 12 | Article 701275
Mohammad et al. Peptide 19-2.5 Attenuates HFD-Induced T2DMovercome, however could use the LBP assay as well as the
endotoxin activity assay (EAA) together with the LAL assay to
confirm the results concluded (9, 71). Our finding here that an
AMP which binds to and inactivates LPS reduces insulin-
resistance, diabetic nephropathy and steatohepatitis supports
the view that metabolic endotoxemia importantly contributes
to their pathogenesis. This hypothesis is further supported by
findings demonstrating that TLR-4 receptor deficient mice fed a
HFD develop less insulin resistance (6, 7).
We have also used a metabolomic approach to gain a better
insight into the effects of the HFD alone and presence of Peptide
19-2.5 on the metabolic phenotype of the animals: There is very
good evidence that L-carnitine is involved in lipid metabolism
and transports fatty acids into the mitochondria to increase the
b-oxidation-mediated metabolism of fats in the liver (72). There
is also good evidence that carnitine plays a role in maintaining
liver function and is critical for choline metabolism. Our
metabolome data showed that treatment of HFD-mice with
peptide 19-2.5 restored serum carnitine level (which were
lower in HFD-mice treated with vehicle). Carnitine is primarily
synthesized from methionine and lysine in the liver and kidney
and is important for the transport of fat into the mitochondria to
generate ATP (26). Carnitine is also frequently used in
supplements for weight loss and this could provide an
explanation for the small reduction in weight loss in mice
treated with Peptide 19-2.5 (73). Oral administration of L-
carnitine improves insulin sensitivity in obese mice and
reduces fasting glucose levels in patients with T2DM (74–76).
In contrast, carnitine deficiency is associated with liver injury
(77). We report here that mice challenged with HFD and treated
with Peptide19-2.5 have restored serum levels of carnitine, which
may have contributed to the beneficial effects of the AMP
reported here.
Limitations of the Study
Adipose tissue macrophages can clear up dead adipocytes which
accumulate during obesity. They can also internalize the excess
free fatty acids which are released by insulin-resistant adipocytes
which requires NOX2. NOX-/- mice in early diet-induced obesity
shown an improvement of metabolic phenotypes, but this does
worsen in late diet-induced obesity (78). Therefore, adipose
tissue macrophages have shown to be critical in characterizing
metabolic syndrome. This study has not addressed the impact of
Peptide 19-2.5 on the activation of adipose tissue macrophages
e.g. by LPS or LP (or other DAMPs or PAMPs known to play a
role in the metabolic syndrome). Future studies are warranted to
address this interesting and potentially important hypothesis.CONCLUSIONS
There is good evidence that metabolic endotoxemia contributes
to the pathophysiology of obesity, metaflammation and diabetes.
We report here for the first time that patients with T2DM have
elevated levels of the human cathelicidin LL-37. The effects ofFrontiers in Immunology | www.frontiersin.org 15LPS-binding proteins in experimental diabetes have not yet been
investigated. To gain a better understanding of the role of LPS-
binding AMPs in the pathophysiology of diabetes, we have
challenged mice with a HFD for 12 weeks in the presence and
absence of the LPS-binding protein, Pep2-5. We report here for
the first time that Peptide 19-2.5 attenuates the IRS-1
phosphorylation in the liver, diabetic nephropathy
(proteinuria), hypercholesterolemia and steatohepatitis caused
by HFD in the mouse. The reductions in liver fat deposition
(liver weight and staining for fat) and steatohepatitis (reduced
activation of NF-kB, inflammasome and release of ALT)
observed in HFD-mice treated with Peptide 19-2.5 are, at least
in part, due to reduced expression of CD36 secondary to
inhibition of ERK-1/2 in the liver. Although difficult to prove,
a reduction in the degree of metabolic endotoxemia may also
have importantly contributed to the observed beneficial effects of
Peptide 19-2.5 in mice challenged with a HFD.DATA AVAILABILITY STATEMENT
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